Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intellipharmaceutics International Inc V.IPCI.H

Alternate Symbol(s):  IPCIQ

Healthcare Biotechnology
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.


TSXV:IPCI.H - Post by User

Intellipharmaceutics International Inc > News?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by OK_tradeon Jan 16, 2020 12:16pm
149 Views
Post# 30560760

RE:News?

RE:News?
This is not right! The company halts the trading yesterday due to pending news. The company resumes trading this morning without the news release. The only "info" I got is from the SH bullboard, a very reliable source. In the mean time SP takes a dive and the volume goes through the roof!
I hope someone from TSX office takes a look at this unacceptable company's behaviour.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities